Yumanity Therapeutics, Inc. (NasdaqCM: YMTX) Loss Submission Form

Kuznicki Law is investigating Yumanity Therapeutics, Inc. (NasdaqCM: YMTX) (the “Company”) regarding (1) the sale of its product candidate, YTX-7739 and Yumanity’s unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV for $26 million in cash; and (2) Yumanity’s proposed merger with Kineta, Inc., pursuant to which current Yumanity stockholders are expected to own only approximately 15% of the combined company.  Kuznicki Law is seeking to determine whether the transactions and the process that led to them are adequate and fair to the Company’s shareholders.